|1.||Kalluri, Raghu: 10 articles (01/2012 - 04/2003)|
|2.||Sugimoto, Hikaru: 7 articles (06/2011 - 04/2003)|
|3.||Maeshima, Yohei: 6 articles (01/2010 - 06/2003)|
|4.||Ramont, Laurent: 5 articles (08/2014 - 12/2004)|
|5.||Sudhakar, Akulapalli: 5 articles (12/2008 - 04/2003)|
|6.||Wang, Wei: 4 articles (01/2015 - 06/2010)|
|7.||Brassart-Pasco, Sylvie: 4 articles (08/2014 - 03/2010)|
|8.||Maquart, François-Xavier: 4 articles (03/2013 - 12/2004)|
|9.||Hamano, Yuki: 4 articles (07/2005 - 06/2003)|
|10.||Hopfer, Helmut: 3 articles (09/2015 - 05/2003)|
|1.||Diabetic Nephropathies (Diabetic Nephropathy)
10/01/2005 - "We previously reported the therapeutic efficacy of antiangiogenic tumstatin peptide in the early diabetic nephropathy model. "
07/01/2004 - "Taken together, these results demonstrate the potential use of antiangiogenic tumstatin peptide as a novel therapeutic agent in early diabetic nephropathy."
07/01/2004 - "Here, we show the effect of tumstatin peptide in inhibiting alterations in early diabetic nephropathy. "
07/01/2004 - "Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy."
07/01/2004 - "Tumstatin peptide is an angiogenesis inhibitor derived from type IV collagen and inhibits in vivo neovascularization induced by vascular endothelial growth factor (VEGF), one of the mediators of glomerular hypertrophy in diabetic nephropathy. "
04/02/2010 - "This assay for tumstatin in biological samples may be helpful in evaluating the therapeutic and/or prognostic value of tumstatin in cancer patients."
05/01/2010 - "This study investigated whether 19-peptide, a fragment of tumstatin, inhibited the growth of gastric tumor cells in vitro and in vivo. "
11/20/2008 - "The study aimed to design and synthesize the small molecular angiogenesis inhibition-related peptide (peptide 21), to replicate the structural and functional features of the active zone of angiogenesis inhibition using tumstatin and to prove that synthesized peptide 21 has a similar activity: specifically inhibiting tumor angiogenesis like tumstatin. "
11/01/2013 - "Thus, ODC overexpression suppresses the expression of tumstatin, which may provide fundamental evidence for the combination of anti-angiogenic therapy and conventional therapy for cancer treatment. "
03/22/2013 - "Tumstatin expression triggered a large decrease in tumor growth and an increase in mouse survival. "
05/09/2006 - "Here, we demonstrate that transplantation of wild-type bone marrow (BM) into irradiated COL4A3(-/-) mice results in a possible recruitment of BM-derived progenitor cells as epithelial cells (podocytes) and mesangial cells within the damaged glomerulus, leading to a partial restoration of expression of the type IV collagen alpha3 chain with concomitant emergence of alpha4 and alpha5 chain expression, improved glomerular architecture associated with a significant reduction in proteinuria, and improvement in overall kidney histology compared with untreated COL4A3(-/-) mice or irradiated COL4A3(-/-) mice with BM from adult COL4A3(-/-) mice. "
03/01/1993 - "By 10-14 d after immunization, the rats had developed circulating anti-GBM antibodies, reactive with the alpha 3 chain of type IV collagen (the Goodpasture antigen), accompanied by proteinuria, accumulation of rat immunoglobulin (Ig)G in the GBM, increased expression of ICAM-1 by glomerular endothelial cells, infiltration of glomerular tufts with LFA-1+ T cells and monocyte/macrophages, and early crescents. "
|4.||Renal Cell Carcinoma (Grawitz Tumor)
09/30/2008 - "The antitumor activity of the tumstatin peptide, in combination with bevacizumab (anti-VEGF antibody), displays significant improvement in efficacy against human renal cell carcinoma xenografts when compared with the single-agent use. "
09/30/2008 - "Collectively, our results demonstrate that tumstatin peptide binds specifically to the tumor endothelium, and its antiangiogenic action is mediated by alphavbeta3 integrin, and, in combination with an anti-VEGF antibody it exhibits enhanced tumor suppression of renal cell carcinoma."
|5.||Hereditary Nephritis (Alport Syndrome)
12/01/2008 - "The results of our study show that Goodpasture antigen detection plays a very important role in differential diagnosis of progressive and nonpregressive hereditary nephritis, particularly in early phases of the disease."
12/01/2008 - "The aim of this study was to determine the significance of Goodpasture antigen detection in diagnosis of progressive and nonprogressive hereditary nephritis in its early phase. "
04/01/1987 - "Recent immunofluorescence studies on the kidneys of most males with hereditary nephritis have demonstrated an absence of Goodpasture antigen (GPA) from glomerular capillary basement membranes (GCBM). "
07/01/1986 - "The Goodpasture antigen in Alport's syndrome: studies with a monoclonal antibody."
12/01/2008 - "In 2 out of 6 patients with unclassified hereditary nephritis, Goodpasture antigen expression was very strong, in one patient it was very reduced, and in 3 patients it was negative. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||Collagen Type IV (Type IV Collagen)
|7.||Messenger RNA (mRNA)
|9.||DNA (Deoxyribonucleic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Transplantation (Transplant Recipients)